Alfacell Corporation to Present at IBC Life Sciences' Antibody Engineering Conference.Company to Discuss Novel Targeted Therapeutics from its RNase Technology Platform BLOOMFIELD, N.J. -- Alfacell Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ACEL ACEL Australian Council for Educational Leaders (Australia) ACEL Aerospace Crew Equipment Laboratory ACEL Alternating Current Electro-Luminescent ), a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease Ribonuclease A group of enzymes, widely distributed in nature, which catalyze hydrolysis of the internucleotide phosphodiester bonds in ribonucleic acid (RNA). (RNase) therapeutics for cancer and other life-threatening diseases, today announced that Dr. Susanna Rybak, a member of Alfacell's Scientific Advisory Board, is an invited speaker at IBC IBC International Building Code IBC Iraq Body Count IBC Institutional Biosafety Committee IBC Inflammatory Breast Cancer IBC International Business Company IBC Independence Blue Cross IBC Insurance Bureau of Canada IBC International Broadcasting Convention Life Sciences' 17th Annual Conference on Antibody Engineering and Immunotherapeutics for the 21st Century, to be held December 10-14, 2006 in San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. , CA. Dr. Rybak's presentation, entitled "RNase-based Targeted Therapeutics," will feature research conducted at the National Cancer Institute and Alfacell involving the Company's lead investigational drug candidate, ONCONASE([R]) (ranpirnase), and, specifically, the creation of an anti-CD22 antibody-ONCONASE molecule that very effectively kills human non-Hodgkin's lymphoma non-Hodg·kin's lymphoma n. Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells. Non-Hodgkin's lymphoma cells. Highlights of work from another Alfacell research collaborator, Dr. Juergen Krauss from the University of Duisburg-Essen The University of Duisburg-Essen (German: Universität Duisburg-Essen) is a university institution situated in the German federal state of North Rhine-Westphalia. , will also be presented. Dr. Krauss's work involves the creation of novel immunomodular forms suitable for specifically targeting ONCONASE to tumors. Dr. Krauss and Alfacell are collaborating to build a portfolio of antibody-ONCONASE targeted immunotherapeutics. For more information about the conference, visit www.ibclifesciences.com/antibodyeng. Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. For more information, please visit http://www.alfacell.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion